In two sep­a­rate moves, Bio­haven seeks to re­pur­pose failed Bris­tol My­ers/Roche Duchenne drug while buy­ing out small biotech

As Bio­haven re­port­ed its fourth quar­ter and full-year 2021 earn­ings to in­vestors, the biotech un­veiled two new deals — a li­cens­ing deal with a Big Phar­ma and an ac­qui­si­tion of a small­er com­pa­ny.

Bio­haven is in-li­cens­ing a Phase III-ready com­pound for spinal mus­cu­lar at­ro­phy from Bris­tol My­ers Squibb, the com­pa­nies said ear­ly Fri­day, in a col­lab­o­ra­tion where the fi­nan­cial in­for­ma­tion is un­known. Bio­haven is al­so buy­ing out Chan­nel Bio­sciences in a deal worth $100 mil­lion up­front in cash and stock, as well as rough­ly $1.14 bil­lion in po­ten­tial mile­stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER